Advertisement

Lysosomal Diseases and Therapeutic Options: An Overview

  • Eveline J. Langereis
  • Frits A. WijburgEmail author
Chapter
First Online:
  • 601 Downloads
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)

Abstract

Lysosomal diseases cover a wide spectrum of inborn metabolic disorders and are characterized by a remarkable variability in pathophysiology and clinical presentation. This first chapter presents an overview of the natural history and biochemical characteristics of lysosomal storage disorders and some of the developments in therapy that have been made in the past decades and a brief look at potential future therapies.

Keywords

Enzyme Replacement Therapy Lysosomal Enzyme Fabry Disease Gauche Disease Glycogen Storage Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Hobbs, J.R., et al.: Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2, 709–712 (1981)PubMedCrossRefGoogle Scholar
  2. 2.
    Brady, R.O., Pentchev, P.G., Gal, A.E., Hibbert, S.R., Dekaban, A.S.: Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s disease. N. Engl. J. Med. 291, 989–993 (1974)PubMedCrossRefGoogle Scholar
  3. 3.
    De Duve, C.: From cytases to lysosomes. Fed. Proc. 23, 1045–1049 (1964)Google Scholar
  4. 4.
    De Duve, C.: Exploring cells with a centrifuge. Science 189, 186–194 (1975)PubMedCrossRefGoogle Scholar
  5. 5.
    Gaucher, P.C.E.: De l’epithélioma primitive de la rate, hypertrophie idiopathique de la rate sans leucémie. PhD thesis, Faculté de Médicine, Paris (1882)Google Scholar
  6. 6.
    Fabry, J.: Ein Beitrag zur Kenntnis der Purpura Haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch. Dermatol. Res. 43, 187–200 (1898)CrossRefGoogle Scholar
  7. 7.
    Anderson, W.: A case of ‘angiokeratoma’. Br. J. Dermatol. 10, 113–117 (1898)CrossRefGoogle Scholar
  8. 8.
    Hunter, C.: A rare disease in two brothers. Proc. R. Soc. Med. 10, 104–116 (1917)PubMedGoogle Scholar
  9. 9.
    Hurler, G.: Ûber einem Typ multipler Abartungen, vorwiegend am Skelettsystem. Z. Kinderheilkd. 24, 220–234 (1919)CrossRefGoogle Scholar
  10. 10.
    Pompe, J.C.: Over idiopatische hypertrofie van het hart. Ned. Tijdschr. Geneeskd. 76, 304–311 (1932)Google Scholar
  11. 11.
    CORI, G.T.: Glycogen structure and enzyme deficiencies in glycogen storage disease. Harvey Lect. 48, 145–171 (1952)PubMedGoogle Scholar
  12. 12.
    HERS, H.G.: Alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe’s disease). Biochem. J. 86, 11–16 (1963)PubMedGoogle Scholar
  13. 13.
    Alberts, B., et al.: Intracellular compartments and protein sorting. In: Alberts, B. (ed.) Molecular Biology of the Cell. Garland Science, New York (2007)Google Scholar
  14. 14.
    Doherty, G.J., McMahon, H.T.: Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 857–902 (2009)PubMedCrossRefGoogle Scholar
  15. 15.
    Storch, S., Braulke, T.: Transport of lysosomal enzymes. In: Saftig, P. (ed.) Lysosomes, Georgetown: Landes Bioscience: Springer Science+Business Media, New York, pp. 17–22 (2005)Google Scholar
  16. 16.
    Desnick, R.J., Thorpe, S.R., Fiddler, M.B.: Toward enzyme therapy for lysosomal storage diseases. Physiol. Rev. 56, 57–99 (1976)PubMedGoogle Scholar
  17. 17.
    Walkley, S.U.: Pathogenic cascades in lysosomal disease—why so complex? J. Inherit. Metab. Dis. 32, 181–189 (2009)PubMedCrossRefGoogle Scholar
  18. 18.
    Schultz, M.L., Tecedor, L., Chang, M., Davidson, B.L.: Clarifying lysosomal storage diseases. Trends Neurosci. 34, 401–410 (2011)PubMedCrossRefGoogle Scholar
  19. 19.
    Parkinson-Lawrence, E.J., et al.: Lysosomal storage disease: revealing lysosomal function and physiology. Physiology (Bethesda) 25, 102–115 (2010)CrossRefGoogle Scholar
  20. 20.
    Weinstein, L.B.: Selected genetic disorders affecting Ashkenazi Jewish families. Fam. Community Health 30, 50–62 (2007)PubMedCrossRefGoogle Scholar
  21. 21.
    Murphy, A.M., Lambert, D., Treacy, E.P., O’Meara, A., Lynch, S.A.: Incidence and prevalence of mucopolysaccharidosis type 1 in the Irish republic. Arch. Dis. Child. 94, 52–54 (2009)PubMedCrossRefGoogle Scholar
  22. 22.
    Poorthuis, B.J., et al.: The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 105, 151–156 (1999)PubMedGoogle Scholar
  23. 23.
    Lin, H.Y., et al.: Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. Am. J. Med. Genet. A 149A, 960–964 (2009)PubMedCrossRefGoogle Scholar
  24. 24.
    van der Ploeg, A.T., Reuser, A.J.: Pompe’s disease. Lancet 372, 1342–1353 (2008)PubMedCrossRefGoogle Scholar
  25. 25.
    Pastores, G.M.: Clinical perspectives. In: Lysosomal storage disorders: principles and practice Pastores, Hackensack NJ: World Scientific, pp. 23–46 (2010)Google Scholar
  26. 26.
    Bellettato, C.M., Scarpa, M.: Pathophysiology of neuropathic lysosomal storage disorders. J. Inherit. Metab. Dis. 33, 347–362 (2010)PubMedCrossRefGoogle Scholar
  27. 27.
    Muenzer, J., Wraith, J.E., Clarke, L.A.: Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123, 19–29 (2009)PubMedCrossRefGoogle Scholar
  28. 28.
    Muenzer, J., et al.: Multidisciplinary management of Hunter syndrome. Pediatrics 124, e1228–e1239 (2009)PubMedCrossRefGoogle Scholar
  29. 29.
    Arn, P., Wraith, J.E., Underhill, L.: Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J. Pediatr. 154, 859–864 (2009)PubMedCrossRefGoogle Scholar
  30. 30.
    Walker, R.W., Darowski, M., Morris, P., Wraith, J.E.: Anaesthesia and mucopolysaccharidoses. A review of airway problems in children. Anaesthesia 49, 1078–1084 (1994)PubMedCrossRefGoogle Scholar
  31. 31.
    Moores, C., Rogers, J.G., McKenzie, I.M., Brown, T.C.: Anaesthesia for children with mucopolysaccharidoses. Anaesth. Intensive Care 24, 459–463 (1996)PubMedGoogle Scholar
  32. 32.
    Hatzmann, J., et al.: Predicting health-related quality of life of parents of children with inherited metabolic diseases. Acta Paediatr. 98, 1205–1210 (2009)PubMedCrossRefGoogle Scholar
  33. 33.
    Fratantoni, J.C., Hall, C.W., Neufeld, E.F.: Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162, 570–572 (1968)PubMedCrossRefGoogle Scholar
  34. 34.
    Sands, M.S., Davidson, B.L.: Gene therapy for lysosomal storage diseases. Mol. Ther. 13, 839–849 (2006)PubMedCrossRefGoogle Scholar
  35. 35.
    Lucke, T., et al.: Developmental outcome in five children with Hurler syndrome after stem cell transplantation: a pilot study. Dev. Med. Child Neurol. 49, 693–696 (2007)PubMedCrossRefGoogle Scholar
  36. 36.
    Boelens, J.J., Prasad, V.K., Tolar, J., Wynn, R.F., Peters, C.: Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr. Clin. North Am. 57, 123–145 (2010)PubMedCrossRefGoogle Scholar
  37. 37.
    Johnson, W.G., et al.: Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. Birth Defects Orig. Artic. Ser. 9, 120–124 (1973)PubMedGoogle Scholar
  38. 38.
    Brady, R.O., et al.: Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry’s disease. N. Engl. J. Med. 289, 9–14 (1973)PubMedCrossRefGoogle Scholar
  39. 39.
    Barton, N.W., et al.: Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med. 324, 1464–1470 (1991)PubMedCrossRefGoogle Scholar
  40. 40.
    Patterson, M.C., Vecchio, D., Prady, H., Abel, L., Wraith, J.E.: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 6, 765–772 (2007)PubMedCrossRefGoogle Scholar
  41. 41.
    Cox, T., et al.: Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481–1485 (2000)PubMedCrossRefGoogle Scholar
  42. 42.
    Seregin, S.S., Amalfitano, A.: Gene therapy for lysosomal storage diseases: progress, challenges and future prospects. Curr. Pharm. Des. 17, 2558–2574 (2011)PubMedCrossRefGoogle Scholar
  43. 43.
    Beck, M.: Therapy for lysosomal storage disorders. IUBMB Life 62, 33–40 (2010)PubMedGoogle Scholar
  44. 44.
    Platt, F.M., Lachmann, R.H.: Treating lysosomal storage disorders: current practice and future prospects. Biochim. Biophys. Acta 1793, 737–745 (2009)PubMedCrossRefGoogle Scholar
  45. 45.
    Hawkins-Salsbury, J.A., Reddy, A.S., Sands, M.S.: Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts? Hum. Mol. Genet. 20, R54–R60 (2011)PubMedCrossRefGoogle Scholar
  46. 46.
    Lachmann, R.H.: Enzyme replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr. 23, 588–593 (2011)PubMedCrossRefGoogle Scholar
  47. 47.
    Cartier, N., et al.: Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818–823 (2009)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of PediatricsAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations

Cite chapter

Buy options